The need for more specialised obesity management, including glucagon‐like peptide 1 (GLP‐1) receptor agonists and other incretin therapies, bariatric surgery referral, behavioural therapy, and additional cardiology or lipid metabolic support, should be assessed on an individual basis and local availability [132, 133, 134]. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.